Director, Facilities
Company: Vaxcyte
Location: San Carlos
Posted on: April 30, 2024
|
|
Job Description:
Company Profile:Vaxcyte, Inc. (Nasdaq: PCVX) is a vaccine
innovation company engineering high-fidelity vaccines to protect
humankind from the consequences of bacterial diseases. The Company
is developing broad-spectrum conjugate and novel protein vaccines
to prevent or treat bacterial infectious diseases. Vaxcyte's lead
candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing
pneumococcal conjugate vaccine (PCV) being developed for the
prevention of invasive pneumococcal disease (IPD). The Company is
re-engineering the way highly complex immunizations are made
through modern synthetic techniques, including advanced chemistry
and our exclusively licensed XpressCFTM cell-free protein synthesis
platform. Unlike conventional cell-based approaches, the Company's
system for producing difficult-to-make proteins and antigens is
intended to accelerate its ability to efficiently create and
deliver high-fidelity vaccines with enhanced immunological
benefits. Vaxcyte's pipeline also includes VAX-31, a 31-valent PCV
candidate; VAX-A1, a prophylactic vaccine candidate designed to
prevent Group A Strep infections; VAX-PG, a therapeutic vaccine
candidate designed to slow or stop the progression of periodontal
disease; and VAX-GI, a vaccine program designed to prevent
Shigella. The Company is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked. For more information, visit
.Vaxcyte, headquartered in San Carlos, CA, went public in June 2020
and currently has a team of approximately 180 employees and
anticipates continued, significant growth. Following equity
offerings in October 2022 and April 2023, which generated over $1.1
billion in net proceeds, the Company's balance sheet is further
strengthened to advance its pipeline of novel vaccines, including
VAX-24. These financings followed positive data readouts from
Vaxcyte's Phase 1/2 proof-of-concept study evaluating VAX-24 in
adults aged 18-64 and Phase 2 study in adults 65 and older. The
Company believes these results support a best-in-class potential
for VAX-24, which was designed to replace the current
standard-of-care in adults and children. VAX-24 is being
investigated for the prevention of IPD, which can be most serious
for infants, young children, older adults and those with immune
deficiencies or certain chronic health conditions. Given the global
impact of pneumococcal disease remains significant, the public
health community continues to advocate for vaccines that can offer
broader protection to prevent IPD. Vaxcyte's PCV franchise,
consisting of VAX-24 and VAX-31, is designed specifically to
address this need and has the potential to deliver the broadest
protection for this very serious disease. We believe that our PCVs
could receive regulatory approval based on successful completion of
clinical studies utilizing well-defined surrogate immune endpoints,
consistent with how other PCVs have obtained regulatory approval in
the past, rather than requiring clinical field efficacy
studies.Summary:Vaxcyte is looking for an energetic and talented
individual to join Vaxcyte's Facilities organization. The primary
function of this Associate Director/Director-level position is to
lead Facilities operations and site services for Vaxcyte's
Headquarters. This position will manage and grow a high-performing
and service-centric team comprised of full-time employees,
contingent workers and 3rd party partners. Beyond functional and
technical experience, primary keys to success for this role focus
on relationships, culture, trust, forward thought, and operational
excellence. This position reports to the Senior Director
Facilities.Note: rotational, shared 24x7 on-call support is
required of this role.Essential Functions:
#J-18808-Ljbffr
Keywords: Vaxcyte, North Highlands , Director, Facilities, Accounting, Auditing , San Carlos, California
Click
here to apply!
|